Which has preferable earnings and valuation, PGNY or CELC?

Progyny has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Progyny $1.29B 1.55 $58.52M $0.77 33.19 Celcuity N/A N/A -$177.04M -$3.90 N/A

Is PGNY or CELC more profitable?

Progyny has a net margin of 5.23% compared to Celcuity's net margin of 0.00%. Progyny's return on equity of 13.34% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Progyny 5.23% 13.34% 9.03% Celcuity N/A -244.61% -50.22%

Does the media favor PGNY or CELC?

In the previous week, Progyny had 8 more articles in the media than Celcuity. MarketBeat recorded 12 mentions for Progyny and 4 mentions for Celcuity. Progyny's average media sentiment score of 0.85 beat Celcuity's score of 0.47 indicating that Progyny is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Progyny 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celcuity 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, PACS or PGNY?

PACS Group has higher revenue and earnings than Progyny. PACS Group is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PACS Group $5.29B 1.10 $191.54M $1.56 23.48 Progyny $1.29B 1.55 $58.52M $0.77 33.19

Is PACS or PGNY more profitable?

Progyny has a net margin of 5.23% compared to PACS Group's net margin of 4.49%. PACS Group's return on equity of 26.47% beat Progyny's return on equity. Company Net Margins Return on Equity Return on Assets PACS Group 4.49% 26.47% 4.36% Progyny 5.23% 13.34% 9.03%

Does the media favor PACS or PGNY?

In the previous week, Progyny had 10 more articles in the media than PACS Group. MarketBeat recorded 12 mentions for Progyny and 2 mentions for PACS Group. Progyny's average media sentiment score of 0.85 beat PACS Group's score of 0.00 indicating that Progyny is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PACS Group 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Progyny 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, PGNY or HIMS?

Hims & Hers Health has higher revenue and earnings than Progyny. Hims & Hers Health is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Progyny $1.29B 1.55 $58.52M $0.77 33.19 Hims & Hers Health $2.35B 2.58 $128.37M -$0.09 N/A

Does the media refer more to PGNY or HIMS?

In the previous week, Hims & Hers Health had 10 more articles in the media than Progyny. MarketBeat recorded 22 mentions for Hims & Hers Health and 12 mentions for Progyny. Progyny's average media sentiment score of 0.85 beat Hims & Hers Health's score of 0.57 indicating that Progyny is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Progyny 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hims & Hers Health 9 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Positive

Is SHC or PGNY more profitable?

Sotera Health has a net margin of 9.91% compared to Progyny's net margin of 5.23%. Sotera Health's return on equity of 39.73% beat Progyny's return on equity. Company Net Margins Return on Equity Return on Assets Sotera Health 9.91% 39.73% 7.05% Progyny 5.23% 13.34% 9.03%

Does the media prefer SHC or PGNY?

In the previous week, Progyny had 9 more articles in the media than Sotera Health. MarketBeat recorded 12 mentions for Progyny and 3 mentions for Sotera Health. Sotera Health's average media sentiment score of 1.10 beat Progyny's score of 0.85 indicating that Sotera Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sotera Health 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Progyny 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CAI or PGNY?

In the previous week, Progyny had 7 more articles in the media than Caris Life Sciences. MarketBeat recorded 12 mentions for Progyny and 5 mentions for Caris Life Sciences. Progyny's average media sentiment score of 0.85 beat Caris Life Sciences' score of 0.45 indicating that Progyny is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caris Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Progyny 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Progyny (PGNY) Competitors

$25.56 0.00 (0.00%)

Closing price 05/29/2026 04:00 PM Eastern

Extended Trading

$25.58 +0.02 (+0.06%)

As of 05/29/2026 07:35 PM Eastern

Compare

PGNY vs. CELC, PACS, HIMS, SHC, and CAI

Should you buy Progyny stock or one of its competitors? MarketBeat compares Progyny with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Progyny include Celcuity (CELC), PACS Group (PACS), Hims & Hers Health (HIMS), Sotera Health (SHC), and Caris Life Sciences (CAI). These companies are all part of the "healthcare" industry.

How does Progyny compare to Celcuity?

Progyny (NASDAQ:PGNY) and Celcuity (NASDAQ:CELC) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Progyny has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.29B	1.55	$58.52M	$0.77	33.19
Celcuity	N/A	N/A	-$177.04M	-$3.90	N/A

Progyny has a net margin of 5.23% compared to Celcuity's net margin of 0.00%. Progyny's return on equity of 13.34% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Progyny	5.23%	13.34%	9.03%
Celcuity	N/A	-244.61%	-50.22%

94.9% of Progyny shares are owned by institutional investors. Comparatively, 63.3% of Celcuity shares are owned by institutional investors. 9.9% of Progyny shares are owned by insiders. Comparatively, 13.3% of Celcuity shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Progyny presently has a consensus target price of $29.55, suggesting a potential upside of 15.59%. Celcuity has a consensus target price of $150.27, suggesting a potential upside of 13.09%. Given Progyny's stronger consensus rating and higher possible upside, equities research analysts plainly believe Progyny is more favorable than Celcuity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Celcuity	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83

Progyny has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market. Comparatively, Celcuity has a beta of 0.1, indicating that its stock price is 90% less volatile than the broader market.

In the previous week, Progyny had 8 more articles in the media than Celcuity. MarketBeat recorded 12 mentions for Progyny and 4 mentions for Celcuity. Progyny's average media sentiment score of 0.85 beat Celcuity's score of 0.47 indicating that Progyny is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Progyny	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celcuity	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Progyny beats Celcuity on 14 of the 16 factors compared between the two stocks.

How does Progyny compare to PACS Group?

PACS Group (NYSE:PACS) and Progyny (NASDAQ:PGNY) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

Progyny has a net margin of 5.23% compared to PACS Group's net margin of 4.49%. PACS Group's return on equity of 26.47% beat Progyny's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PACS Group	4.49%	26.47%	4.36%
Progyny	5.23%	13.34%	9.03%

PACS Group currently has a consensus target price of $48.00, suggesting a potential upside of 31.07%. Progyny has a consensus target price of $29.55, suggesting a potential upside of 15.59%. Given PACS Group's higher probable upside, equities research analysts plainly believe PACS Group is more favorable than Progyny.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PACS Group	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Progyny	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

94.9% of Progyny shares are held by institutional investors. 70.1% of PACS Group shares are held by company insiders. Comparatively, 9.9% of Progyny shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

PACS Group has higher revenue and earnings than Progyny. PACS Group is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PACS Group	$5.29B	1.10	$191.54M	$1.56	23.48
Progyny	$1.29B	1.55	$58.52M	$0.77	33.19

In the previous week, Progyny had 10 more articles in the media than PACS Group. MarketBeat recorded 12 mentions for Progyny and 2 mentions for PACS Group. Progyny's average media sentiment score of 0.85 beat PACS Group's score of 0.00 indicating that Progyny is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PACS Group	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Progyny	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Progyny beats PACS Group on 10 of the 16 factors compared between the two stocks.

How does Progyny compare to Hims & Hers Health?

Progyny (NASDAQ:PGNY) and Hims & Hers Health (NYSE:HIMS) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Progyny has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market. Comparatively, Hims & Hers Health has a beta of 2.37, meaning that its stock price is 137% more volatile than the broader market.

In the previous week, Hims & Hers Health had 10 more articles in the media than Progyny. MarketBeat recorded 22 mentions for Hims & Hers Health and 12 mentions for Progyny. Progyny's average media sentiment score of 0.85 beat Hims & Hers Health's score of 0.57 indicating that Progyny is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Progyny	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hims & Hers Health	9 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Positive

Progyny currently has a consensus price target of $29.55, indicating a potential upside of 15.59%. Hims & Hers Health has a consensus price target of $28.70, indicating a potential upside of 9.88%. Given Progyny's stronger consensus rating and higher possible upside, analysts clearly believe Progyny is more favorable than Hims & Hers Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Hims & Hers Health	2 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.12

Hims & Hers Health has higher revenue and earnings than Progyny. Hims & Hers Health is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.29B	1.55	$58.52M	$0.77	33.19
Hims & Hers Health	$2.35B	2.58	$128.37M	-$0.09	N/A

Progyny has a net margin of 5.23% compared to Hims & Hers Health's net margin of -0.56%. Progyny's return on equity of 13.34% beat Hims & Hers Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Progyny	5.23%	13.34%	9.03%
Hims & Hers Health	-0.56%	6.10%	1.52%

94.9% of Progyny shares are held by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are held by institutional investors. 9.9% of Progyny shares are held by company insiders. Comparatively, 11.8% of Hims & Hers Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Progyny beats Hims & Hers Health on 11 of the 17 factors compared between the two stocks.

How does Progyny compare to Sotera Health?

Sotera Health (NASDAQ:SHC) and Progyny (NASDAQ:PGNY) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, profitability and media sentiment.

Sotera Health has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market. Comparatively, Progyny has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market.

Sotera Health has higher earnings, but lower revenue than Progyny. Progyny is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sotera Health	$1.16B	3.83	$77.94M	$0.41	38.15
Progyny	$1.29B	1.55	$58.52M	$0.77	33.19

Sotera Health has a net margin of 9.91% compared to Progyny's net margin of 5.23%. Sotera Health's return on equity of 39.73% beat Progyny's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sotera Health	9.91%	39.73%	7.05%
Progyny	5.23%	13.34%	9.03%

91.0% of Sotera Health shares are held by institutional investors. Comparatively, 94.9% of Progyny shares are held by institutional investors. 15.4% of Sotera Health shares are held by insiders. Comparatively, 9.9% of Progyny shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Sotera Health currently has a consensus price target of $20.33, suggesting a potential upside of 30.01%. Progyny has a consensus price target of $29.55, suggesting a potential upside of 15.59%. Given Sotera Health's higher possible upside, research analysts clearly believe Sotera Health is more favorable than Progyny.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sotera Health	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.70
Progyny	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

In the previous week, Progyny had 9 more articles in the media than Sotera Health. MarketBeat recorded 12 mentions for Progyny and 3 mentions for Sotera Health. Sotera Health's average media sentiment score of 1.10 beat Progyny's score of 0.85 indicating that Sotera Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sotera Health	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Progyny	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Sotera Health beats Progyny on 9 of the 17 factors compared between the two stocks.

How does Progyny compare to Caris Life Sciences?

Caris Life Sciences (NASDAQ:CAI) and Progyny (NASDAQ:PGNY) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability and risk.

Caris Life Sciences presently has a consensus target price of $27.56, indicating a potential upside of 64.81%. Progyny has a consensus target price of $29.55, indicating a potential upside of 15.59%. Given Caris Life Sciences' higher probable upside, analysts clearly believe Caris Life Sciences is more favorable than Progyny.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caris Life Sciences	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Progyny	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

Progyny has higher revenue and earnings than Caris Life Sciences. Caris Life Sciences is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caris Life Sciences	$812.03M	5.82	-$68.09M	-$7.61	N/A
Progyny	$1.29B	1.55	$58.52M	$0.77	33.19

In the previous week, Progyny had 7 more articles in the media than Caris Life Sciences. MarketBeat recorded 12 mentions for Progyny and 5 mentions for Caris Life Sciences. Progyny's average media sentiment score of 0.85 beat Caris Life Sciences' score of 0.45 indicating that Progyny is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caris Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Progyny	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

94.9% of Progyny shares are held by institutional investors. 50.0% of Caris Life Sciences shares are held by company insiders. Comparatively, 9.9% of Progyny shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Progyny has a net margin of 5.23% compared to Caris Life Sciences' net margin of 3.75%. Caris Life Sciences' return on equity of 98.28% beat Progyny's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caris Life Sciences	3.75%	98.28%	48.87%
Progyny	5.23%	13.34%	9.03%

Summary

Progyny beats Caris Life Sciences on 11 of the 16 factors compared between the two stocks.

Get Progyny News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PGNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PGNY vs. The Competition

Export

Metric	Progyny	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.00B	$8.52B	$6.57B	$12.58B
Dividend Yield	N/A	1.76%	2.68%	5.31%
P/E Ratio	33.19	21.99	21.59	26.25
Price / Sales	1.55	19.93	561.77	114.93
Price / Cash	34.72	12.89	27.44	37.60
Price / Book	4.27	5.13	10.04	6.86
Net Income	$58.52M	$175.77M	$3.56B	$337.26M
7 Day Performance	2.73%	2.88%	2.82%	3.58%
1 Month Performance	N/A	N/A	N/A	-0.79%
1 Year Performance	16.93%	5.69%	37.62%	39.67%

Progyny Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PGNY Progyny	4.4959 of 5 stars	$25.56 flat	$29.55 +15.6%	+16.9%	$2.00B	$1.29B	33.19	310	Insider Trade Buyback Announcement
CELC Celcuity	2.3957 of 5 stars	$138.23 flat	$149.30 +8.0%	+1,145.4%	$6.74B	N/A	N/A	40	Analyst Forecast
PACS PACS Group	3.8604 of 5 stars	$37.78 +0.1%	$48.00 +27.1%	+268.8%	$5.97B	$5.29B	24.22	47,455	Analyst Upgrade
HIMS Hims & Hers Health	3.0978 of 5 stars	$23.71 -0.2%	$28.90 +21.9%	-54.0%	$5.41B	$2.35B	N/A	2,442	Analyst Forecast Insider Trade
SHC Sotera Health	3.7764 of 5 stars	$15.66 flat	$20.33 +29.8%	+27.6%	$4.47B	$1.16B	38.20	3,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PGNY) was last updated on 6/1/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Progyny (PGNY) Competitors

PGNY vs. CELC, PACS, HIMS, SHC, and CAI

How does Progyny compare to Celcuity?

Summary

How does Progyny compare to PACS Group?

Summary

How does Progyny compare to Hims & Hers Health?

Summary

How does Progyny compare to Sotera Health?

Summary

How does Progyny compare to Caris Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGNY vs. The Competition

Progyny Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Progyny (PGNY) Competitors

PGNY vs. CELC, PACS, HIMS, SHC, and CAI

How does Progyny compare to Celcuity?

Which has preferable earnings and valuation, PGNY or CELC?

Is PGNY or CELC more profitable?

Do institutionals and insiders hold more shares of PGNY or CELC?

Do analysts rate PGNY or CELC?

Which has more volatility & risk, PGNY or CELC?

Does the media favor PGNY or CELC?

Summary

How does Progyny compare to PACS Group?

Is PACS or PGNY more profitable?

Do analysts rate PACS or PGNY?

Do institutionals and insiders have more ownership in PACS or PGNY?

Which has stronger earnings & valuation, PACS or PGNY?

Does the media favor PACS or PGNY?

Summary

How does Progyny compare to Hims & Hers Health?

Which has more risk & volatility, PGNY or HIMS?

Does the media refer more to PGNY or HIMS?

Do analysts prefer PGNY or HIMS?

Which has higher earnings and valuation, PGNY or HIMS?

Is PGNY or HIMS more profitable?

Do institutionals & insiders believe in PGNY or HIMS?

Summary

How does Progyny compare to Sotera Health?

Which has more volatility & risk, SHC or PGNY?

Which has higher earnings and valuation, SHC or PGNY?

Is SHC or PGNY more profitable?

Do institutionals and insiders believe in SHC or PGNY?

Do analysts prefer SHC or PGNY?

Does the media prefer SHC or PGNY?

Summary

How does Progyny compare to Caris Life Sciences?

Do analysts prefer CAI or PGNY?

Which has preferable earnings & valuation, CAI or PGNY?

Does the media prefer CAI or PGNY?

Do insiders and institutionals believe in CAI or PGNY?

Is CAI or PGNY more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGNY vs. The Competition

Progyny Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools